[ad_1]
The National Agency for Health Surveillance (Anvisa) has published the registration of generic levofloxacin hemihydrate as a solution for infusion. The drug is indicated to treat bacterial infections, such as respiratory tract infections, skin infections, urinary tract infections and bones.
"By registering the generic drug, Anvisa guarantees the quality of the product,
Another benefit of granting the registration, according to the release, is the reduction in the cost of treatment, as it has been proven that the drugs were a therapeutic equivalent of the reference medicine, the generic drugs must enter the market with a value at least 35% lower than that of the reference medicine
[ad_2]
Source link
